Gold vs US Dollar

Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Get Started

Cozart Investors - CZT

Share Name	Share Symbol	Market	Stock Type
Cozart	CZT	London	Ordinary Share

	Price Change	Price Change %	Share Price	Last Trade
	0.00	0.00%	57.50	01:00:00

Open Price	Low Price	High Price	Close Price	Previous Close
			57.50	57.50

more quote information »

Top Investor Posts

Top Posts
Posted at 02/3/2007 08:08 by etarip Cozart PLC 02 March 2007 Cozart plc Acquisition of Nemesis Scientific Limited Expansion of presence in the workplace drug testing market Abingdon, 2 March, 2007, Cozart plc ('Cozart' or the 'Company'), the medical diagnostics company, today expanded its presence in the workplace drug testing market with the acquisition of Nemesis Scientific Limited ('Nemesis'). Nemesis is a provider of workplace drug and alcohol testing services and products to a blue-chip client base. Nemesis offers a variety of services including 24 hour 'round the clock' sample collection and pre-employment, random and 'for-cause' drug testing. Nemesis has established a network of 86 collection agents in the UK and overseas, and provides the workplace customer with a full range of services from drug testing policy provision through to training, sample collection, drug testing and result review. Cozart is currently active in the workplace drug testing sector with clients in the UK and continental Europe. The acquisition enables Cozart to integrate Nemesis' services with the Company's own drug testing products and services: on-site saliva and urine testing systems together with laboratory screening and confirmation testing. This complete offering will allow Cozart to compete both in the UK and internationally with a more comprehensive workplace service offering. In the year ended September 2006, the unaudited accounts of Nemesis show turnover of £705k, profit before tax of £88k and net assets of £48k. The upfront cash consideration of £1.14m will be financed (net of expenses) by a vendor placing of 3,636,363 new Cozart ordinary shares with institutional and other investors. The vendor placing has been fully underwritten at 33p per share ('the Placing Price') by Numis Securities, nominated adviser and stockbroker to Cozart. In addition to the institutional investors, Edgar Wallner, a non-executive director of the Company will be subscribing for 1,200,000 shares at the Placing Price under the same terms as the institutional investors. Following the vendor placing, Edgar Wallner will be interested in 14,215,933 ordinary shares in the Company, representing 13.3% of the Company's enlarged issued share capital. The shares are expected to be admitted to trading on AIM on 8 March 2007. In addition, earn out consideration of £0.4m will be payable upon the achievement of revenue targets in the first two years following completion. The acquisition is expected to be earnings enhancing in the first full year of ownership. Commenting on the acquisition of Nemesis, Dr. Chris Hand, Chief Executive of Cozart, said: 'Drug testing in the workplace is increasingly common place as employers and employees recognise its importance, especially in sectors where safety is paramount. The acquisition of Nemesis expands Cozart's position in this rapidly growing market and brings a blue chip customer base and strong product offering to the group.' ----------------------------------------------------------------------------- A show of confidence by Mr Edgar Wallner Read Full Thread Reply
Posted at 25/1/2007 10:16 by cfb2 shuisky: Given the technical achievements of joint Philips venture (new stuff on Cozart's website under investor relations) I'd say that it's looking quite likely that they're going to take up the offer. Issuance of shares would result in ~5% dilution. However, offset that against the increased valuation of Cozart from a joint commercial deal with Philips and I don't think this is going to be a "cap". I mentioned it because now is the time to consider the ramifications. From the presentation... System detects opiates (morphine) at European cut offs (30ng/ml) in less than one minute For the same cut off, the previous DDS was taking 5 minutes. CFB Read Full Thread Reply
Posted at 04/9/2006 17:51 by wengerb Etarip: no, I don't think that CZT should be looking to change its PR company. CZT employs Financial Dynamics, a company with an excellent reputation. Whilst I'm on the subject of advisors, CZT's broker/financial advisor, Numis, also has a very good reputation, especially in the Health Science sector. But your specific question raises a more general point. I assume that most of we few who read this BB are optimistic about CZT's prospects but feel always slightly starved of insight into what's going on in the company. We've invested in CZT and would love to know whether we're going to see a return in the short, medium or long-term. Me, I'm in for the long ride. I don't believe that the really significant potential will begin to appear until late-2007, with news of the Phillips joint development. Why doesn't the company keep us better informed? Why doesn't the company seem to be more actively massaging its share price? I have a friend who's an FD in a company rather similar to CZT and he once said to me "If this was a private company in which we'd all invested, we wouldn't worry so much. We know what we want the company to achieve. We know the company's competitive advantages. We should all relax and let the company get on with things. The problem is that if you're a small, developing company we all, especially the outside investors, think that the share price is a predictor of whether or not we'll succeed. But it isn't. We all know that but we can't stop worrying that it might be." For obvious reasons, a company has to walk the tightrope of keeping its owners, the shareholders, informed of progress (or lack of it) whilst not spilling the beans to the company's competitors. CZT tells us (something of) what's going on twice a year and is under an obligation to tell us more if, between those reports, the company's fortunes take a turn for the worse or better. Forgive me if I seem to be telling everybody what is perfectly obvious but the point I'm trying to get to is that many companies, and I suspect that CZT is one of them, do not give a very high priority to its short-term share price. As a company manager, you don't want to greatly upset your shareholders but you hope that the shareholders realise that the directors' main responsibility is to maximise the ultimate value of the shares, not to waste time or money trying to move the share price from 34p to 40p when there's not a lot to shout about. Nearly 50% of the CZT shares are held by two key directors of CZT (the brothers Hand) and by a non-exec. director. The non-exec has continued to invest large sums in CZT. These people have a hugely better informed view of CZT's prospects that we'll ever have. We outsiders have the option of trusting these people or of getting out of our investment. As I mentioned yesterday, why would the key directors of a company raise the issue of possible sales developments in Germany and the US if they didn't have a reasonable faith that such developments will occur? I'm not being sarcastic when I say that when writing up the prelims, directors don't (I hope) say "This report looks a bit thin. What can we stick in to bulk it up a bit? I know, Germany and the US are big markets, let's hint that we might be doing a bit of business with them? After all, if we never get anywhere in Germany and the US, nobody will ever remember that we floated the idea." CZT places huge store on the Phillips project. I don't know whether Phillips approached CZT or vice versa but I do know that one of the world's most successful players in the medical equipment market is very actively engaged with a small company outside Didcot. The directors of CZT know how frequent are the visits to Eindhoven. They know how much resource Phillips is putting into the project. The bosses at CZT must have a feeling for how well the joint development will play out. When it was first announced, in January of this year, the initial development time was set at 18-months. That's a pretty rapid development project and almost half the time has already elapsed. I'm not suggesting for a moment that I have a good reason to believe that the Phillips joint development has a high likelihood of succeeding. Joint developments often fail. What we do know is that the main shareholders in Cozart (who just happen to run the company) do seem to be optimistic about the outcome. One might ask the question; if the project's going so well now, why wouldn't Phillips simply buy CZT tomorrow? I once asked a similar question of the strategic boss of a drug development company. He explained that great big companies are often happier to leave the risk and reward to smaller partners. Smaller partners are more energetic and nimble at driving development projects. If the big company ends up paying much more to acquire the smaller company, it's still a better bet for the larger. Read Full Thread Reply
Posted at 14/8/2006 15:24 by cfb2 Gombie: A couple of news articles about roadside drug testing being likely in the UK in the next couple of years - WengerB posted one of them - maybe investors were hoping for a quicker decision? The sells were taken on by WINS and EVO who both immediately dropped their bid price (WINS now has an almost 15% spread so isn't interested in making a market). The current bid price is being solely held by the house broker NUMS, which by my estimates has only about 500K of stock left over from the fundraising @ 28p so, for probably self indulgent reasons, doesn't want to drop its offer price. CFB Read Full Thread Reply
Posted at 08/8/2006 08:15 by wengerb JL. Forgive me but I don't quite see what Medisys events have to do with the market capitalisation of Cozart. Medisys has taken a rather small stake in Cozart, presumably in the hope that Cozart will prosper. Cozart might help Medisys but I don't see how the reverse can happen to any great degree. My reference to "several weeks" refers to Cozart's prelims (which are due, I believe, towards the end of September). My hunch is that these might pleasantly surprise the market. We can then expect Numis (which seems to have done an excellent job in placing the new Cozart shares in the past few days) to issue new guidance and to start to try to warm up institutional investors. Read Full Thread Reply
Posted at 31/7/2006 10:41 by cfb2 Not a particularly exciting acquisition as Cozart already have a presence in Scandinavia having bought Medib. It brings in some institutional investors (including Medisys - which has a chequered background itself), which is not a bad thing, but I'd have thought paying £1m for a company with a pretax profit of £100K is only just about worth it in terms of due diligence. Maybe I'm missing something but unless HL were seen as competitors I just can't see this as a strategic move - however, they do have the potential of sales in the Swedish criminal justice which is a market that they know well from the UK. I hope that wasn't the only reason that they bought HL. CFB Read Full Thread Reply
Posted at 18/7/2006 00:38 by cfb2 biswell: It appears that you have developed a following with your infamous charting ability. Readers following this "astute" investor might like to read the following post: And jonno6 recommended viewing Cozart against the FTSE:AIM Index which shows a remarkable similarity - not surprising for a share which is low volume. Assuming jonno6 hasn't shot himself through boredom, I'll leave him to shoot down your more recent charts, which to even my basic charting skills look like you've left off a number of interesting resistance lines. CFB Read Full Thread Reply
Posted at 10/7/2006 17:57 by biswell YasO, VOG may well have put the worst behind it, ie the bottom is most likely now in at 82p ish....AJ is an olde poster who I have crossed swords with many times on another website years back before sparring again on this one. At one point i think he had it in for me bigtime because I disagreed with some of his views. However over the years I would like to think we have gained each others respect and olde grudges are now dead and buried.His point re Natgas price is valid , and has been in my opinion for the last 3 months....however not before at xmas time. So any lift now in Natgas will mean big gains for VOG. I have looked at the SEO chart and that also seems to be at a bottom at the recent 8.1p placing price. I think there will be some +ve news coming from negotiations with Walmart and Asda soon now as they have been on going for quite a while, as have various tests and trials .... check out recent RNS's .... also they have got FDA approval in the US .... SEO was one of the top most popular shares last year with investors ... it's fall from grace could I think represent a buying opportunity. Regards CZT .... RNS's and recent news flow have not done the trick. When the specs are released the cat will be out the bag and the share price will suffer I think. regards B Read Full Thread Reply
Posted at 22/5/2006 20:53 by adeyberry Sorry, but I'm confused..... That idiot biswell was very pro CZT a few weeks ago, but is now trying to scare investors into selling!??!!? Notice he has edited all his posts from a while back!!! Does one feel, in the current market climate, he has filled his nappies and sold short, hoping all will follow him!???! Or is he a paid ramper/deramper, and his boss has told him to try and get the price down now!?!? Sad! Read Full Thread Reply
Posted at 20/5/2006 16:56 by biswell I have just read some replies to enquiries I have out and this is worthy of some thought/comment........ Cozart as investors know has contracts in place with the Home Office which expire in 2008. Some olde worthy investor might like to enlighten me when they come up for renewal , as they have in the past , on a forward rolling programme. The reason I ask is this snippet ... 'The Home Office Scientific Development Branch (HOSDB) is developing a sophisticated device that is expected to be able to detect and identify all drugs, including illicit drugs, prescription and over-the-counter medicines. It will be a couple of years before this device might be available and type-approved for use as the scientific development work behind it is highly complex. When the work is completed, HOSDB will write a full specification for commercial manufacturers to make and market the device. The HOSDB is also currently developing a device for measuring driver impairment. If the development is successful, the device will be capable of screening for all types of driver impairment not just drug impairment. Police will then be able to use the device in place of the field impairment tests currently employed. B Read Full Thread Reply

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions